New Cetuximab Dosing Guidelines Approved for Colorectal Cancer and Head and Neck Cancer

The FDA has approved a new dosing regimen of 500 mg/m2 cetuximab (Erbitux®, Eli Lilly) for patients with KRAS wild-type epidermal growth factor receptor (EGFR)–expressing metastatic colorectal cancer (CRC) and patients with head and neck squamous cell carcinoma (HNSCC). This biweekly dosage regimen serves as an alternative to the existing weekly dosage regimen of cetuximab, whether on its own or combined with chemotherapy, and should be administered as a single 120-minute intravenous infusion ev...
Continue reading

NSAIDs Increase Survival for PIK3CA-altered Head and Neck Cancer

According to a new study, over-the-counter non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, have been found to significantly increase survival in patients with PIK3CA-altered head and neck squamous cell carcinoma (HNSCC). A mutation in PIK3CA, the gene encoding p110a and the catalytic subunit of phosphoinositide-(3)-kinase a, commonly occurs in HNSCC. In prior research, a sample of 504 patients with HNSCC tumors yielded 174 tumors containing a PIK3CA mutation. In patients with HN...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.